NMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nomura Holdings Inc (NMR) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive signs, including a recent analyst upgrade to Buy and bullish moving averages, but the setup is not compelling enough to buy aggressively at the current price. Since you are impatient and want a direct answer, my view is: hold and wait rather than buy now.
NMR is in a mildly bullish trend overall because SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which supports a positive long-term structure. However, momentum is mixed: the MACD histogram is slightly negative and contracting, suggesting the near-term push is weakening. RSI_6 at 71.52 indicates the stock is near overbought conditions, so upside from here may be limited in the short term. Price at 9.06 is sitting just below R1 at 9.113 and above the pivot at 8.883, meaning it is not at an attractive discount. The technical picture is constructive but not a high-conviction entry.
["BofA upgraded Nomura to Buy from Neutral on 2026-06-25.", "BofA raised its price target to $10.20 from $9.40, implying upside from the current $9.06 level.", "Analyst expects real estate disposal to boost net income.", "BofA believes ROE should stay near 11%, supporting a healthier earnings profile.", "Bullish moving average alignment suggests the broader trend remains favorable."]
["No news flow in the past week, so there is no fresh catalyst driving the stock higher right now.", "MACD momentum is slightly negative and weakening.", "RSI is elevated near overbought territory, reducing near-term entry attractiveness.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Insiders are neutral with no significant trading trends over the last month.", "No recent congress trading data or influential figure buying/selling activity was reported.", "Options implied volatility is extremely high, which usually reflects elevated uncertainty and expensive positioning."]
No usable financial snapshot was available because the provided data returned an error. As a result, there is no latest quarter revenue or earnings breakdown to assess directly. The only financial-related insight available comes indirectly from analyst commentary: BofA expects real estate disposal to improve net income and believes ROE can remain near 11%, which is supportive of longer-term profitability. The latest quarter season could not be identified from the provided data.
Analyst sentiment has improved recently: on 2026-06-25, BofA upgraded Nomura to Buy from Neutral and increased the price target to $10.20 from $9.40. The stated rationale was stronger relative valuation and expected net income support from real estate disposal, with ROE near 11% viewed positively. Wall Street pros currently look constructive on valuation and earnings support, while the main con is that the stock has already moved into a less attractive short-term technical position and lacks fresh news momentum. Overall analyst tone is positive, but not strong enough alone to justify an immediate aggressive buy.
